ARWR Arrowhead Pharmaceuticals
- 22.060
- -0.020-0.09%
- 22.060
- 0.0000.00%
Arrowhead Pharmaceuticals News
Arrowhead Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Arrowhead Pharmaceuticals Is Maintained at Equal-Weight by Morgan Stanley
Damo: Maintaining the Arrowhead Pharma (ARWR.US) rating, adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, and the target price was adjusted from $36.00 to $27.00.
Damo: Maintaining the Arrowhead Pharma (ARWR.US) rating, adjusted from a shareholding wait-and-see rating to a shareholding wait-and-see rating, and the target price was adjusted from $36.00 to $27.00.
Morgan Stanley Maintains Equal-Weight on Arrowhead Pharma, Lowers Price Target to $27
Morgan Stanley analyst Michael Ulz maintains Arrowhead Pharma with a Equal-Weight and lowers the price target from $36 to $27.
Selling Arrowhead Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
Even though Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) has fallen by 12% over the past week , insiders who sold US$3.1m worth of stock over the past year have had less luck. Insiders would probabl
HC Wainwright & Co. Reiterates Buy on Arrowhead Pharma, Maintains $90 Price Target
HC Wainwright & Co. analyst Patrick Trucchio reiterates Arrowhead Pharma (NASDAQ:ARWR) with a Buy and maintains $90 price target.
Arrowhead Pharmaceuticals Reports Substantial Fiscal Q2 Loss, Diverging From Analyst Expectations
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Diodes Incorporated (NASDAQ:DIOD) fell sharply during Friday's session after the company reported worse-than-expected quarterly financial results.Diodes posted adjusted earnings of 28 cents
Earnings Call Summary | Arrowhead Pharmaceuticals(ARWR.US) Q2 2024 Earnings Conference
The following is a summary of the Arrowhead Pharmaceuticals, Inc. (ARWR) Q2 2024 Earnings Call Transcript:Financial Performance:Arrowhead Pharmaceuticals reported a net loss of $125.3 million or $1.02
UBS Cuts Price Target on Arrowhead Pharmaceuticals to $71 From $75, Keeps Buy Rating
Arrowhead Pharmaceuticals (ARWR) has an average rating of outperform and price targets ranging from $27 to $90, according to analysts polled by Capital IQ. Price: 22.11, Change: -2.61, Percent Change:
Arrowhead Pharmaceuticals Is Maintained at Buy by Chardan Capital
Arrowhead Pharmaceuticals Is Maintained at Buy by Chardan Capital
Arrowhead Pharmaceuticals Shares Are Trading Lower After the Company Reported Q2 Financial Results.
Arrowhead Pharmaceuticals Shares Are Trading Lower After the Company Reported Q2 Financial Results.
Chardan Capital Maintains Buy on Arrowhead Pharma, Maintains $60 Price Target
Chardan Capital analyst Keay Nakae maintains Arrowhead Pharma with a Buy and maintains $60 price target.
Arrowhead Pharma Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 158.56% Chardan Capital $60 → $60 Maintains Buy 02/08/2024 287.85% HC Wainwright & Co. → $90 Re
Piper Sandler Keeps Their Buy Rating on Arrowhead Pharmaceuticals (ARWR)
Arrowhead Pharmaceuticals | 10-Q: Quarterly report
Arrowhead Pharma Q2 2024 GAAP EPS $(1.02) Misses $(0.12) Estimate
Arrowhead Pharma (NASDAQ:ARWR) reported quarterly losses of $(1.02) per share which missed the analyst consensus estimate of $(0.12) by 750 percent.
Arrowhead Pharmaceuticals 2Q Loss/Shr $1.02 >ARWR
Arrowhead Pharmaceuticals 2Q Loss/Shr $1.02 >ARWR
Arrowhead Pharmaceuticals Reports Fiscal 2024 Second Quarter Results
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2024 second quarter ended March 31, 2024. The Company is hosting a conference call today, May 9, 2024, at 4:30 p.m. ET to discuss the results.
Arrowhead Pharmaceuticals(ARWR.US) Director Sells US$41,934.69 in Common Stock
$Arrowhead Pharmaceuticals(ARWR.US)$ Director Vakiener Victoria sold 1,799 shares of common stock on May 2, 2024 at an average price of $23.31 for a total value of $41,934.69.Source: Announcement What
Arrowhead Nets $50 Milestone Payment From Royalty Pharma After Completion of Enrollment in Trial of Cardiovascular Drug
Arrowhead Pharmaceuticals (ARWR) said Thursday it received a $50 million milestone payment from Royalty Pharma (RPRX) after completion of the enrollment of a phase 3 trial of olpasiran, a potential ca
Analysis
Price Target
No Data
